End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
829.8 INR | -1.18% |
|
-2.77% | +26.28% |
15/05 | Granules India posts Q4 revenue fall on weak paracetamol sales, price erosion | RE |
25/04 | Transcript : Glenmark Life Sciences Limited, Q4 2024 Earnings Call, Apr 25, 2024 |
Business Summary
Number of employees: 1,824
Sales per Business
INR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Generic
93.0
%
| 19,154 | 90.2 % | 20,099 | 93.0 % | +4.93% |
CDMO
7.0
%
| 1,720 | 8.1 % | 1,513 | 7.0 % | -12.05% |
Sales per region
INR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
India
52.4
%
| 21,232 | 100.0 % | 11,330 | 52.4 % | -46.64% |
International
47.6
%
| - | - | 10,282 | 47.6 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Yasir Rawjee
CEO | Chief Executive Officer | 58 | 13/19/13 |
Director of Finance/CFO | - | 01/22/01 | |
Compliance Officer | - | 23/21/23 | |
Chief Tech/Sci/R&D Officer | - | 14/20/14 | |
Vinod Naik
BRD | Director/Board Member | - | 12/20/12 |
Mathew George
LAW | General Counsel | - | 01/19/01 |
Sumantra Mitra
HRO | Human Resources Officer | 49 | 11/18/11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Manju Agarwal
BRD | Director/Board Member | 66 | 30/20/30 |
Yasir Rawjee
CEO | Chief Executive Officer | 58 | 13/19/13 |
Sumantra Mitra
HRO | Human Resources Officer | 49 | 11/18/11 |
Director/Board Member | 64 | 08/21/08 | |
Vinod Naik
BRD | Director/Board Member | - | 12/20/12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 122,527,172 | 19,263,516 ( 15.72 %) | 0 | 15.72 % |
Company contact information
Glenmark Life Sciences Ltd.
4th Floor, OIA House 470 Cardinal Gracious Road
400099, Mumbai
+91 22 6829 7979
http://www.glenmarklifesciences.com![address Glenmark Life Sciences Limited(GLS)](https://cdn.zonebourse.com/static/address/126415448.png)
Sector
Sales per Business
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.28% | 121.64Cr | |
+51.63% | 80TCr | |
+41.51% | 63TCr | |
-5.10% | 36TCr | |
+19.90% | 33TCr | |
+9.95% | 30TCr | |
+17.66% | 24TCr | |
+3.39% | 23TCr | |
+10.75% | 21TCr | |
+6.99% | 17TCr |
- Stock Market
- Equities
- GLS Stock
- Company Glenmark Life Sciences Limited